Drug Profile
Verinurad - AstraZeneca
Alternative Names: RDEA-3170Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ardea Biosciences
- Developer Ardea Biosciences; AstraZeneca
- Class Antigouts; Antihyperglycaemics; Heart failure therapies; Naphthalenes; Propionic acids; Pyridines; Small molecules; Uricosurics; Urologics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gout; Heart failure; Hyperuricaemia; Kidney disorders; Type 2 diabetes mellitus
- No development reported Renal failure
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Kidney-disorders(Combination therapy, In volunteers) in Germany (PO, Controlled release)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Renal-failure(Combination therapy, In volunteers, In adults) in Germany (PO, Controlled release)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Renal-failure(Combination therapy, In volunteers, In adults) in Germany (PO, Immediate release)